Immutep Ltd (IMMP) News & EventsIMMPImmutep Ltd

Immutep Granted New Patent for Cancer Treatment

Immutep announced the grant of a new patent entitled "Combined Preparations for the Treatment of Cancer or Infection" by the United States Patent and Trademark Office, or USPTO. This patent is the fourth in the series and follows the grant of the United States parent patent, first divisional patent, and second divisional patent announced in December 2020, March 2021 and June 2023, respectively. The claims of the new patent build on the protection provided by the three previously granted patents and are directed to methods for the treatment of cancer by administering eftilagimod alfa in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody, or fragments thereof. The expiry date of the patent is January 20, 2036.

Immutep Presents First Clinical Data for IMP761 at Rheumatology Congress

Immutep announced it will present first-in-human clinical data for its lead autoimmune candidate, IMP761, at the European Alliance of Associations for Rheumatology Congress. Initial clinical findings showed significant and clinically relevant pharmacodynamic activity, including reduction of local inflammatory responses and attenuated T-cell activity compared to placebo. "I am very excited about this first clinical evaluation of IMP761. IMP761 is designed to selectively target overactive T cells linked to chronic inflammation and is now showing clear immunosuppressive effects at dose levels above 0.9 mg/kg in this placebo controlled Phase I study. IMP761 could be positioned to address significant unmet need across multiple autoimmune indications such as rheumatoid arthritis or other T cell driven conditions," said Frederic Triebel, CSO of Immutep.

Major Averages Rise as Markets Watch Iran Negotiations

The major averages were broadly higher near noon as markets head toward a weekly gain despite continued volatility. Treasury yields have eased, lifting megacaps and chip stocks, though markets continue to be on watch for signs of a breakthrough in negotiations to end the war in Iran.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Estee Lauderand Puigannounced that the partiesregarding a potential business combinationImaxis exploring a sale, according toWorkdayreportedand reiterated its FY27 revenue guidanceZoom Communicationsprovided areport for Q1Deckers Outdoorreportedand provided its outlook for FY272. WALL STREET CALLS:JPMorganSweetgreenon ramping brand transformationViking Holdingsto Buy at Truist on strong demand trendsJefferiesGeneracon data center contract potentialSummit Therapeuticsto Neutral at H.C. WainwrightInspire Medicalto Underperform at BofA on coding overhang3. AROUND THE WEB:Nintendo's"Tomodachi Life: Living the Dream" was the top-selling physical video game in Japan for the week of May 11-17 with 98,092 copies sold during the week, bringing the game's lifetime sales in Japan to 1.14M, Famitsu reportsSony'sBungie plans to lay off a significant number of workers as it concludes active development on "Destiny 2," Bloomberg saysMicrosoftcommercial chief marketing officer Yusuf Mehdi, a 35-year company veteran, is set to depart after the next fiscal year according to an internal memo, Business Insider reportsStarbucksshut down an AI program for automating inventory counts, nine months after deploying it, after it frequently miscounted and mislabeled items, Reuters saysSamsungis set to distribute about $26.6B to its 78,000 chip employees, or a $340,000 bonus to each, in early 2027 as part of a last-minute labor union deal, Bloomberg reports4. MOVERS:Pelotongains after beingin the S&P 600Rocket Labsincreases after completing itsfor SynspectiveFutu Holdingsand UP Fintechfall in New York afterChina has launched a broad crackdown on unauthorized cross-border investingCAElower in New York afterand setting long-term financial targets for FY30ImmunityBiodeclines afteron NMIBC and presenting preliminary results from a new health economic analysis on that ANKTIVA plus Bacillus Calmette-Guerin5. EARNINGS/GUIDANCE:BJ's Wholesaleand backed its guidance for FY26 after what CEO Bob Eddy called "a strong first quarter"Take-Two, with EPS missing consensusBooz Allenand provided guidance for FY27Ross Stores, with EPS and revenue beating consensusGlobal Ship Lease (GSL), with EPS lower year-over-yearINDEXES:Near midday, the Dow was up 0.81%, or 408.71, to 50,694.37, the Nasdaq was up 0.63%, or 164.99, to 26,458.08, and the S&P 500 was up 0.66%, or 49.08, to 7,494.80.